Resources

Genoskin raises $8.7M series Ato support drug development with ethical, human-based modelsFunding to accelerate global expansion and strengthen scientific leadership We are excited to announce that Genoskin, a leader in developing ex vivo human skin platforms for testing drugs and medical devices, has raised $8.7 million (€8M) in Series A funding. The investment will fuel the company’s global expansion, enhanceRead more

Explore how HypoSkin®—a standardized, injectable, and immunocompetent human skin model—provides a translational, animal-free solution for assessing the immunogenicity of therapeutic compounds. From structural stability to real-time immune response profiling, this white paper delivers data-backed insights designed for pharma and biotech teams advancing injectable drug development.

Top-level science through the eyes of an expert.Join us for the next session of Naked Immunology Webinar series, where we explore cutting-edge advancements in drug delivery and therapeutic innovation. In this session we will discuss how the immune system’s reaction to neuromuscular blockers could offer new therapeutic insights. WATCH NOWThis webinar explores new insights into the antibody responses of patientsRead more

Explore how NativeSkin® supports ethical, human-relevant, and translational research for pharma.

Top-level science through the eyes of an expert.Skin Deep: how microbes & immunity shape allergic reactionsDid you miss the live session? You can now watch the full webinar replay on demand where Dr. Phlipp Starkl explores how the skin’s immune system balances protection and pathology in response to microbial threats. In this webinar, Dr. Philipp Starkl shared his latest researchRead more

Vaccine DevelopmentVaxSkin® an innovative platform to study vaccine immunogenicityIntroduction The field of drug development is witnessing a remarkable surge in the development of innovative strategies. There is a need to develop technological platforms capable of generating human data prior to progressing to clinical trials. Developing safe and effective vaccines requires a clear understanding of early immune responses at the injectionRead more